# Comorbidities and Outcome of Geriatric COVID-19 Patients Admitted to Chittagong Medical College Hospital

Mahmud Hassan Arif<sup>1\*</sup> Rana Chowdhury<sup>2</sup> Taznuba Tahreen<sup>3</sup> Md Abdus Sattar<sup>4</sup>

### **Abstract**

**Background:** The 2019 Corona Virus illness (COVID-19) is a novel disease with a notable mortality risk, and it has been noted that older adults have a higher death risk from COVID-19. There was a scarcity of studies on comorbidity patterns and outcomes of COVID-19 in Bangladeshi geriatric patients. The study aimed to investigate the comorbidities and outcomes of geriatric COVID-19 patients admitted to a tertiary hospital in Bangladesh.

Materials and methods: This prospective observational study was carried out at Chittagong Medical College Hospital (CMCH) in Six months' timeduration from 01/07/2021 to 31/12/2021. 110 RT-PCR COVID-19positive geriatric patients admitted to CMCH during the study period were included in the study. Consecutive sampling was followed in the study. The data collected included the patient's age, sex, comorbidities, severity of illness, and outcome.

Results: The mean age was 60.0±7.4 years with a maleto-female ratio of 1.6:1. The most frequent comorbidity was hypertension (75.5%), followed by DM (68.2%), IHD (26.4%), COPD (18.2%), CKD (18.2%) and stroke (6.4%). Out of 110patients, only 5 (4.5%) patients were free from any comorbidity, 31 (28.18%) patients had single comorbidity, 40 (36.4%) patients reported having two comorbidities, and another 34 (30.9%) had 3 comorbidities. Thirty-seven (33.6%) patients expired, and seventy-three (66.4%) patients were recovered and discharged. Higher age, unvaccinated status, and higher number of comorbidities were significantly associated with mortality.

Conclusion: The current investigation verified that in older COVID-19 patients, more comorbidities and age were linked to a higher risk of death.

Key words: COVID-19; Comorbidity; Elderly; Outcome.

1. Assistant Professor of Medicine ☐ Chittagong Medical College, Chattogram. 2. Medical Officer, OSD, DGHS. 3. Lecturer of Anatomy □ Southern Medical College, Chattogram. 4. Professor of Medicine ☐ Chittagong Medical College, Chattogram. \*Correspondence: Dr. Mahmud Hassan Arif

Cell: 01711 88 31 86 E-mail: arif.mahmud@gmail.com

Submitted on □ 18.04.2024 Accepted on  $\square$ :  $\square 20.05.2024$ 

#### Introduction

The global population is currently underwent a demographic transition, characterized by a significant increase in the proportion of older individuals. This phenomenon, known as population aging, is being observed in the majority of countries around the globe. The life expectancy at birth in Bangladesh has witnessed significant growth over the years. In 1960, the average life expectancy was recorded at 47 years. However, by 2018, this figure had risen to 71 years for males and 74 years for females.<sup>2</sup> The rise in life expectancy has led to a corresponding increase in the senior population, hence presenting numerous issues for the nation.3 The elderly population in Bangladesh is commonly seen as vulnerable due to their reliance on family support, disadvantaged socio-economic circumstances, limited educational attainment, inadequate access to healthcare facilities, presence of multiple health issues and absence of comprehensive social security initiatives.<sup>4,5</sup> Recent research has provided a comprehensive analysis of the impact of COVID-19 on older persons with Non-Communicable Diseases (NCDs), shedding light on the significant disruption of crucial public health services in Bangladesh.<sup>6</sup> The issue of healthcare accessibility for elderly individuals with non-communicable chronic illnesses has been a longstanding concern within Bangladeshi culture, predating the COVID-19 epidemic. Regrettably, the current global health crisis has this exacerbated predicament.<sup>7</sup> Approximately 6.7% of the overall COVID-19 patient population in Bangladesh consisted of older individuals, with fatalities within this age cohort being nearly 39% of the total number of deaths.<sup>8</sup> As the progression of the pandemic has unfolded, there has been a notable surge in the availability of clinical data originating from Bangladesh. The objective of this study was to provide current data regarding the co morbidity profile and prognosis of COVID-19 among elderly individuals in Bangladesh. Furthermore, this study

also aimed to examine the impact of several clinical and laboratory indicators, as well as comorbidities, on the prognosis of COVID-19 in elderly individuals.

# Materials and methods

This prospective observational study was carried out at Chittagong Medical College Hospital (CMCH) in Six months' time duration from 01/07/2021 to 31/12/2021. 110 RT-PCR COVID-19 positive geriatric patients admitted to CMCH during the study period was included in the study. Consecutive sampling was followed in the study. Patients admitted to the COVID block with confirmed COVID-19 (Positive RT-PCR of a nasopharyngeal swab and age: 60 years or more were included in this study.

Study was conducted after getting approvals from the Ethical Review Committee of Chittagong Medical College. Participation was voluntary. Written informed consent was obtained from the patients or care givers of the patients after a full explanation of the study procedure and purposes. All measures were taken to maintain data confidentiality.

#### **Results**

In the study, 130 patients were screened for the eligibility in the study. Twenty of them were excluded for not meeting the eligibility criteria, and the rest 110 were included in the study.

The most frequent co morbidity in the studied patients was hypertension (75.5%), followed by DM (68.2%), IHD (26.4%), COPD (18.2%), CKD (18.2%), and stroke (6.4%) (Table I).

**Table I** Co morbidity pattern among the study patients (n=110)

Co morbiditypatterns□	Frequency Percentage	
Hypertension□	83 □	75.5
Diabetes mellitus □	75□	68.2
Ischaemic heart disease□	29□	26.4
Chronic obstructive pulmonary disease	□ 20□	18.2
Chronic kidney disease□	13□	11.8
Stoke□	7□	6.4
Malignancy□	1 🗆	0.9
Tuberculosis□	1 🗆	0.9
Chronicliver disease □	1□	0.9

During admission, majority of the patients were either in moderate (56/110, 50.9%) or in severe (51/110, 46.4%) clinical stage of the diseases. Only, 3 (2.7%) of the patients were in critical stage (Figure 1).




Figure 1 Clinical severity grading of the patients (n=110)

The most frequent complications were respiratory failure, ARDS, and MOF/Shock in the studied patients and 30 (27.3%) patients needed ICU support.

**Table II** In-hospital complications of the patients (n=110)

Variables□	Frequency□	Percentage
Complications□		
Respiratory failure□	43 □	39.1
$ARDS \square$	29□	26.4
$AMI/HF \square$	$2\square$	1.8
$AKI\square$	9□	8.2
MOF/Shock□	27□	25.5
ICU requirement□	30□	27.3

Out of 110 included patients 37 expired in hospital giving a mortality rate of 33.6%. 73 (66.4%) patients were discharged after recovery, among them 44 patients (40%) were discharged after recovery without in-hospital complications and 29 patients (26.4%) were discharged after recovery with in-hospital complications.

**Table III** In-hospital outcome of the patients (n=110)

Variables□	Frequency□ P	ercentage
Finaloutcome		
Recovered and discharged		
(With or without complications)	73 (29+44)□	66.4
Deceased□	37□	33.6
Referral□	00 🗆	00

Age played an important role as shown by the significant difference between survived and deceased patients in Table III. The difference in the proportion between the two groups varied as age increased. The proportion of deceased patients aged 60 69 was significantly smaller than that of surviving patients whereas the proportion of deceased patients aged 80 or above was significantly larger than that of surviving patients (p = 0.016). Sex did not appear to be a mortality risk factor as demonstrated by the insignificant

difference in the male proportion between the deceased and surviving group. None of the fully vaccinated patients died in the hospital compared to the 30 (81.1%) deceased patients who were unvaccinated. Smoking behavior did not appear to be a mortality risk factor as demonstrated by the insignificant difference in the smokers' proportion between the deceased and surviving group (p=0.847).

**Table IV** Demographic characteristics, vaccination status, and Smoking behavior between survived and deceased patients (n=110)

In-hospital outcome		
Survived (n=73)□	Deceased (n=37)□	p value
57 (78.1)□	19 (51.4)	
11 (15.1)□	12 (32.4)□	0.016
5 (6.8)□	6 (16.2)□	
46 (63.0)□	22 (59.5)	
27 (37.0)□	15 (40.5)□	0.717
21 (28.0)□	0 (0)	
50 (68.5)□	7 (18.9)	
2 (2.7)□	30 (81.1)□	< 0.001
31 (42.5)□	15 (40.5)	
er□ 42 (27.2)□	22 (59.5)□	0.847
	Survived (n=73)  57 (78.1)  11 (15.1)  5 (6.8)  46 (63.0)  27 (37.0)  21 (28.0)  50 (68.5)  2 (2.7)  31 (42.5)	Survived (n=73)□ Deceased (n=37)□         57 (78.1)□       19 (51.4)         11 (15.1)□       12 (32.4)□         5 (6.8)□       6 (16.2)□         46 (63.0)□       22 (59.5)         27 (37.0)□       15 (40.5)□         21 (28.0)□       0 (0)         50 (68.5)□       7 (18.9)         2 (2.7)□       30 (81.1)□         31 (42.5)□       15 (40.5)

The difference in the proportion between the two groups varied as the presence of hypertension and DM. The proportion of deceased patients with HTN and DM age was higher than that of surviving patients, but the difference reached statistical significance only for the presence of DM. Other individual comorbidity did not appear to be a mortality risk factor as demonstrated by the insignificant difference in the diseased proportion between the deceased and survived group. The difference in the proportion between the two groups varied as the total number of comorbidities increased. The proportion of deceased patients with ≤1 comorbidity was significantly smaller than that of surviving patients whereas the proportion of deceased patients with  $\geq 3$  comorbidity was significantly larger than that of surviving patients (p = 0.008).

**Table V** Co-morbidity pattern between survived and deceased patients (n=110)

Variables 🗆	•	$\begin{array}{ccc} & \text{In-hospitaloutcome} \square & \text{p value}^* \\ \text{urvived (n=73)} \square \text{Deceased (n=37)} \square \end{array}$			
Individual comorbidity					
Hypertension□	51 (69.9)□	32 (86.5)□ 0.056			
Diabetes mellitus □	44 (60.3)□	31 (83.8) □ 0.012			
Ischaemic heart disease □	17 (23.3)□	12 (32.4)□ 0.304			
$COPD\square$	14 (19.2)□	6 (16.2)□ 0.704			
Chronic kidney disease ☐	7 (9.6)□	6 (16.2)□ 0.309			
Total number of comorbio	lity				
≤1 comorbidity □	31 (42.5)□	5 (13.5)			
2 comorbidity□	24 (32.9)□	16 (43.2)□ 0.008			
≥3 comorbidity □	18 (24.7)□	16 (43.2)□			

Table 6shows that the mean pulse rate, temperature, respiratory rate, and neutrophil percentage were significantly higher among the deceased group than the surviving group. Similarly, the median CRP, serum ferritin, D-dimer, RBS and creatinine levels were significantly higher among the deceased group than the surviving group. The mean lymphocyte percentage was lower in the deceased group than in the surviving group.

Table VI shows that among the complicated cases, cardiac involvement (AMI / HF) resulted the highest (100%) death followed by MOF/shock (96.4%), and then, respiratory failure cases (69.7%). Patients with AKI were the largest (44.44%) group alive, followed by ARDS (37.9%). However, there are% cases with multiple complications

**Table VI** Outcome of the complicated patients (n=110)

			_		
Complication□	$\text{Total}(n)\square$	Alive (n) $\square$	Alive (%)□	Death□	Death (%)
Respiratory failure	43□	13□	30.23%□	30□	69.77%
ARDS $\square$	29□	11□	37.93%□	18□	62.07%
AMI/HF □	$2\square$	$0\square$	0%	$2\square$	100%
AKI □	9□	4□	44.44%□	5□	55.56%
MOF/ Shock $\square$	28□	1 🗆	3.58%□	27□	96.42%
Total					

<sup>\*</sup>Multiple complications observed.

# Discussion

In the present study, the most frequent comorbidity was hypertension present in three-quarters of the patients, followed by DM, IHD, COPD, CKD and stroke. Other chronic illnesses like malignancy, chronic liver diseases and tuberculosis were reported less frequently by the

study patients. Among the older COVID-19 patients, hypertension, heart and cerebrovascular diseases, and diabetes were the most prevalent comorbidities. <sup>9</sup> The infrequent comorbidities were coexisting infection with HIV and hepatitis B, malignancy, respiratory illnesses, renal disorders, and immune deficiencies. 10 However, estimations of cardiovascular, diabetes, and hypertension showed significant variation in the number of comorbidities, but not respiratory system disease in this study.11 Hypertension, diabetes, and cardiovascular diseases were the most prevalent comorbidities among patients infected with COVID-19, according to a nationwide study conducted in Bangladesh that thoroughly examines the relationship and influence of concurrent illnesses and health ailments on the severity, hospitalization and outcome in older individuals with the virus. 12

In global public health, the simultaneous presence of chronic diseases in older people is a common issue. 13 An individual suffering from at least three illnesses with distinct pathologies and no mutual reliance at the same time is said to have more than three chronic diseases, accounting for over half of older people in developed nations.<sup>14</sup> Studies in Bangladesh suggest that more than 50 percent of hospitalized older adults have two or more chronic diseases. Present study findings confirmed these pictures of high burden of comorbidity in hospitalized elderly COVID-19 patients. Out of 110 patients, only 5 (4.5%) patients were free from any comorbidity in the present study. Forty (36.4%)patients reported having twocomorbidities, another 34 (30.9%) had three or more comorbidities and 31 (28.18%) patients had single comorbidity. 68.8% of participants in the Li et al. research 26 had one or more comorbidities. The study found that COPD, diabetes, hypertension and cardiovascular disease were the most often occurring comorbid  $illnesses. \\^{15}$ 

During admission, the majority of the patients were either in moderate (50.9%) or in the severe (46.4%) clinical stage of the diseases, and only, 2.7% of the patients were in the critical stage. The admission staging of the patients depends on the hospital policy. According to Liu et al. study, the majority of cases (64.7%) had been categorized as mild at admission, 33 percent as severe and 2% as critical. The admission of the patients depends on the hospital policy. According to Liu et al. study, the majority of cases (64.7%) had been categorized as mild at admission, 33 percent as severe and 2% as critical.

The current study's heightened death rate of 33.6% (37/110) is in keeping with other earlier studies on COVID-19 patients, which highlight the significant influence of age on death and fatality ratios across the lifetime, leading to much higher death rates in the elderly. 18-20

The present investigation improved our knowledge of mortality in elderly patients based on age stratification. The percentage of patients who passed away between the ages of 60 and 69 was considerably lower than the percentage of patients who survived, whereas the percentage of patients who passed away at the age of 80 or beyond was significantly higher. According to a new study, morality was considerably higher unvaccinated COVID-19 among participants than among vaccinated participants (11.17% VS. 1.53%), which examined hospitalization and mortality rates among COVID-19 patients in Bangladesh based on vaccination status.<sup>21</sup> The current investigation emphasized the significance of COVID-19 vaccinations in lowering mortality and validated these findings in elderly patients. The negligible difference in the number of ex- or current smokers between the death and surviving group suggests that smoking habit was not found to be a risk factor for mortality. The available data point to a potential negative effect of smoking on hospitalized COVID-19 patients' illness severity and mortality, which is especially noticeable in younger individuals without diabetes. The results of this study, which lacked a control group, may provide some insight into the relationship between comorbidities and mortality among COVID-19 patients 60 years of age or older. The current investigation found that COVID-19 elderly people with comorbidities had a dismal prognosis, in line with the research that is currently accessible. 22-23 Compared to the number of patients who survived, the percentage of DM patients who died was noticeably greater. In comparison to surviving patients, the share of deceased patients with 1 comorbidity was considerably lower, while the number of deceased patients with 3 comorbidity was substantially greater.

### Limitations

The major limitation of this study lies in its descriptive design, It would be better if we could do an analytical study from the geriatric

population with COVID-19. Another limitation of this study was small sample size. However, we believe that this study will enrich our knowledge on the effects of COVID-19 among the neglected older adults and will guide us to prepare a strategy to improve thecare of the elderly in any future epidemic condition.

#### Conclusion

In conclusion, the study confirmed that elderly patients of COVID-19 have a high comorbidity burden and higher mortality rate. The most frequent comorbidities were hypertension, diabetes, and IHD. Higher age, unvaccinated status, higher number of comorbidities, elevated pulse rate, temperature, respiratory rate, neutrophil percentage, CRP, serum ferritin, D-dimer, RBS and creatinine levels were risk factors for mortality for the elderly patients of COVID-19.

## Recommendation

Further analytical studies on large populations from differient centres are recommended for actual picture of the country.

# Acknowledgement

The authors expressed their gratitude to the all respondents.

# **Contribution of authors**

MHA-Conception, acquisition of data, drafting & final approval.

RC-Data analysis, critical revision & final approval.

TT-Interpretation of data, drafting & final approval.

MAH-Design, interpretation of data, critical revision & final approval.

# Disclosure

All the authors declared no competing interest.

# References

- **1.**□United Nations. Department of Economic and Social Affairs. Population Division. World population ageing 2020 highlights: Living arrangements of older persons. UN. 2020.
- **2.**□Report on Bangladesh sample vital statistics 2018. Dhaka: Bangladesh Bureau of Statistics; 2019.
- **3.** Kabir R, Khan HT, Kabir M, Rahman MT. Population ageing in Bangladesh and its implication on health care. European Scientific Journal. 2013;9(33):34-47.

- **4.** Banna MH, Sayeed A, Kundu S, Christopher E, Hasan MT, Begum MR, et al. The impact of the COVID-19 pandemic on the mental health of the adult population in Bangladesh: a nationwide cross-sectional study. International Journal of Environmental Health Research. 2022;32(4):850-861.
- **5.** Ferdousi NA. Protecting Elderly People in Bangladesh: An Overview. JurnalUndang-undangdanMasyarakat. 2020;24:69-77.
- **6.** A syndemic perspective on the management of non-communicable diseases amid the COVID-19 pandemic in low-and middle-income countries. Frontiers in public health. 2020;8:508.
- **7.** Mistry SK, Ali AM, Yadav UN, Ghimire S, Hossain MB, Das Shuvo S, et al. Older adults with noncommunicable chronic conditions and their health care access amid COVID-19 pandemic in Bangladesh: Findings from a cross-sectional study. PLoS One. 2021;16(7):e0255534.
- **8.**□Institute of Epidemiology, Disease Control and Research (IEDCR), Covid-19 status for Bangladesh. https://www.iedcr.gov.bd/.
- **9.** Paudel SS. A meta-analysis of 2019 novel corona virus patient clinical characteristics and comorbidities. ResearchSquare.2020.
- **10.** Baradaran A, Ebrahimzadeh MH, Baradaran A, Kachooei AR. Prevalence of comorbidities in COVID-19 patients: A systematic review and meta-analysis. Archives of Bone and Joint Surgery. 2020;8(Suppl 1):247-255.
- **11.** Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis. 2020;94(1):91-95.
- **12.** Sharif N, Opu RR, Ahmed SN, Sarkar MK, Jaheen R, Daullah MU, et al. Prevalence and impact of comorbidities on disease prognosis among patients with COVID-19 in Bangladesh: A nationwide study amid the second wave. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2021;15(4):102148.
- **13.** Marengoni A, Angleman S, Melis R, Mangialasche F, Karp A, Garmen A, et al. Aging with multimorbidity: A systematic review of the literature. Ageing research reviews. 2011;10(4):430-439.
- **14.** American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity. Guiding principles for the care of older adults with multimorbidity: An approach for clinicians. Journal of the American Geriatrics Society. 2012;60(10):E1-25.
- **15.** Li P, Chen L, Liu Z, Pan J, Zhou D, Wang H, et al. Clinical features and short- term outcomes of elderly patients with COVID-19. International Journal of Infectious Diseases. 2020;97:245-250.

- **16.** □Dai SP, Zhao X, Wu JH. Effects of Comorbidities on the Elderly Patients with COVID-19: Clinical Characteristics of Elderly Patients Infected with COVID-19 from Sichuan, China. J Nutr Health Aging. 2021;25(1):18-24.
- 17. Liu Y, Mao B, Liang S, Yang JW, Lu HW, Chai YH, et al. Association between ages and clinical characteristics and outcomes of coronavirus disease 2019. European Respiratory Journal. 2020.
- **18.** □ Mendes A, Serratrice C, Herrmann FR, Genton L, Périvier S, Scheffler M, et al. Predictors of in-hospital mortality in older patients with COVID-19: The COVID Age study. Journal of the American Medical Directors Association. 2020;21(11):1546-1554.
- **19.** Chen T, Dai Z, Mo P, Li X, Ma Z, Song S, et al. Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China: A single-centered, retrospective study. The Journals of Gerontology: Series A. 2020;75(9):1788-1795.

- **20.** □Sun H, Ning R, Tao Y, Yu C, Deng X, Zhao C, et al. Risk factors for mortality in 244 older adults with COVID-19 in Wuhan, China: a retrospective study. Journal of the American Geriatrics Society. 2020;68(6):E19-23.
- **21.** Rahman MS, Harun MG, Sumon SA, Mohona TM, Abdullah SA, Khan MN, et al. Hospitalization and Mortality by Vaccination Status among COVID-19 Patients Aged ≥25 Years in Bangladesh: Results from a Multicenter Cross- Sectional Study. Vaccines. 2022;10(12):1987.
- **22.** Bangladesh Bureau of Statistics. Elderly population in Bangladesh: Current features and Future Perspectives. Population Monograph. 2015;4:36. □
- **23.** Sun H, Ning R, Tao Y, Yu C, Deng X, Zhao C, et al. Risk factors for mortality in 244 older adults with COVID 19 in Wuhan, China: a retrospective study. Journal of the American Geriatrics Society. 2020;68(6):E19-23.